Clinical trials: Celiac Disease
Celiac Disease
Latiglutenase as a Treatment for Celiac Disease
Single Center, Randomized, Double-Blind, Placebo Controlled, Gluten Challenge Trial in Patients with Well-Controlled Celiac Disease
- Trial name
- NCT03585478
- Testing
- Latiglutenase
- Where
- United States
- Volunteers
- 79 people
- Sponsor
- Immunogenics, LLC
Celiac Disease
Evaluating the Efficacy and Tolerability of ZED1227 in Subjects With Non-responsive Celiac Disease
A study to discover if ZED1227 can improve continued celiac disease symptoms despite a gluten-free diet
- Trial name
- CEC-013/CEL (NCT07298343)
- Testing
- ZED1227 + SIGE
- Where
- Germany
- Volunteers
- 356 people
- Sponsor
- Dr. Falk Pharma GmbH
Celiac Disease
A Study of Guselkumab in Adult Participants With Celiac Disease
The purpose of this study is to evaluate the safety and tolerability of guselkumab compared to placebo in participants with celiac disease.
- Trial name
- NCT04704843
- Testing
- Guselkumab
- Where
- 4 sites in United States
- Sponsor
- Janssen Research & Development, LLC
Celiac Disease
Study of the Safety, Tolerability and Pharmacokinetics of TIMP-GLIA in Subjects With Celiac Disease
This study is to characterize the safety and tolerability of an investigational drug called TIMP-GLIA when either one or two intravenous doses are given to subjects with celiac disease.
- Trial name
- NCT03486990
- Testing
- TIMP-GLIA
- Where
- 4 sites in United States
- Volunteers
- 23 people
- Sponsor
- Takeda
Celiac Disease
Evaluation of the Efficacy and Safety of ALV003 in Symptomatic in Celiac Disease Patients
To determine the effects of 12 weeks administration of different dose levels of ALV003 on the mucosal lining of the small intestine and symptoms in celiac disease patients.
- Trial name
- NCT01917630
- Testing
- ALV003
- Where
- 88 sites in United States, Canada and 4 more
- Volunteers
- 500 people
- Sponsor
- Alvine Pharmaceuticals Inc.
Healthy, Lupus
Direct to Patient Minimal Risk Biospecimen and Data Collection Research
This study aims to help researchers better understand health conditions and develop improved tests, treatments, and cures for diseases.
- Conditions
- Healthy, Lupus, Celiac, Kidney Disease
- Trial name
- JBMR (NCT07128966)
- Testing
- Observation
- Where
- United States
- Volunteers
- 100,000 people, healthy volunteers welcome
- Sponsor
- Joined Bio
Ulcerative Colitis, Crohn Disease
Systems Biology of Gastrointestinal and Related Diseases
This is a longitudinal observational study on patients with gastrointestinal and related disease. The study will be conducted for at least 10 years, following each participant over time, as they either go through relapses and…
- Conditions
- Ulcerative Colitis, Crohn Disease, Obesity, Colon Polyp
- Trial name
- NCT05579444
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Viome
Irritable Bowel Syndrome, Crohn Disease
Evaluation of the SIMBA Capsule for Small Intestinal Dysbiosis
The SIMBA Capsule is a small, single-use, ingestible capsule that allows for the non-invasive sampling of small bowel contents using purely mechanical means.
- Conditions
- Irritable Bowel Syndrome, Crohn Disease, Celiac Disease, Ulcerative Colitis
- Trial name
- NCT05633706
- Testing
- fluid biopsy capsule
- Where
- Canada
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Nimble Science Ltd.
Non-Celiac Gluten Sensitivity
Efficacy of Probiotic ES1 for the Treatment of Non-Celiac Gluten Sensitivity
Study to demonstrate the efficacy of Probiotic ES1 in alleviating symptoms of gluten sensitivity in non-celiac gluten sensitive subjects exposed to a small, fixed amount of gluten.
- Trial name
- NCT02810301
- Testing
- Probiotic ES1
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- Exzell Pharma Inc.
Celiac Disease
Evaluation of Patient Reported Outcome Instruments in Celiac Disease Patients
This is an evaluation of celiac-specific patient reported outcome instruments in celiac disease patients.
- Trial name
- NCT01560169
- Where
- 10 sites in United States, Canada
- Volunteers
- 110 people
- Sponsor
- Alvine Pharmaceuticals Inc.
Celiac Disease
Dose-Ranging Study of the Efficacy and Safety of TAK-101 for Prevention of Gluten-Specific T Cell Activation in Participants With Celiac Disease on a Gluten-Free Diet
The main aim of the study is to assess if TAK-101 can reduce gluten related symptoms and immune activation in adult participants with celiac disease (CeD) on a gluten-free diet (GFD).
- Trial name
- NCT04530123
- Testing
- TAK-101, Gluten
- Where
- 48 sites in United States, Australia and 2 more
- Volunteers
- 102 people
- Sponsor
- Takeda
Celiac Disease
A Randomized, Double-Blind, Placebo Controlled, Crossover Trial to Evaluate Safety and Efficacy of AGY in Celiac Disease
To assess the efficacy and safety of AGY vs placebo when administered to individuals age 10 to 65 years with medically proven CD and on a gluten free diet
- Trial name
- AGY-010 (NCT03707730)
- Testing
- AGY
- Where
- 2 sites in Canada
- Volunteers
- 161 people
- Sponsor
- Igy Inc.
Diabetes Mellitus, Type 1
Supplementation With B. Infantis for Mitigation of Type 1 Diabetes Autoimmunity
Investigator initiated, randomised, placebo-controlled, double-blind, multi-centre primary intervention study to assess whether daily administration of B.
- Trial name
- SINT1A (NCT04769037)
- Testing
- B. infantis
- Where
- 8 sites in Belgium, Germany and 3 more
- Volunteers
- 1,149 people, healthy volunteers welcome
- Sponsor
- Helmholtz Zentrum München
Coeliac Disease, Celiac Disease
Safety Study of Nexvax2 in Subjects With Coeliac Disease
The main purpose of this study is to determine the safety of weekly injections of Nexvax2 given for three weeks to patients with coeliac disease who have been on a gluten-free diet.
- Trial name
- NCT00879749
- Testing
- 9 micrograms Nexvax2, 30 micrograms Nexvax2, 90 micrograms Nexvax2
- Where
- 2 sites in Australia
- Volunteers
- 34 people
- Sponsor
- Nexpep Pty Ltd
Celiac Disease, Intestinal Disease
Bioequivalence Study of Nexvax2 in Subjects With Celiac Disease
A randomized, double-blind, placebo-controlled clinical study in non-homozygous human leukocyte antigen (HLA)-DQ.2.5+ adults with celiac disease (CeD).
- Conditions
- Celiac Disease, Intestinal Disease, Malabsorption Syndromes, Gastrointestinal Disease
- Trial name
- NCT03543540
- Testing
- Nexvax2
- Where
- 3 sites in Australia
- Volunteers
- 14 people
- Sponsor
- ImmusanT, Inc.
Celiac Disease
Prospective, Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Symptomatic CD Patients
This is a phase 2b, multicenter, prospective, randomized, double-blind, placebo-controlled, crossover study in symptomatic celiac disease patients attempting a GFD for at least one year prior to screening.
- Trial name
- NCT04243551
- Testing
- Latiglutenase
- Where
- United States
- Volunteers
- 83 people
- Sponsor
- Entero Therapeutics
Celiac Disease, Coeliac Disease
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GSK3915393 in Healthy Participants and to Evaluate the Interaction Between GSK3915393 and Grapefruit Juice and Itraconazole
This is a 3-part first time into human study (FTIH) study for GSK3915393. Parts A and B of the study will evaluate the safety, tolerability and pharmacokinetics (PK) of single ascending and repeat oral doses of GSK3915393 in…
- Trial name
- NCT04604795
- Testing
- GSK3915393 Capsules, GSK3915393 Solution for Infusion, Itraconazole
- Where
- United Kingdom
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Celiac Disease
A Double-blind Placebo-controlled Study to Evaluate Larazotide Acetate for the Treatment of Celiac Disease
A randomized, double-blind, placebo-controlled Phase 2B study to evaluate the efficacy and safety of Larazotide Acetate in the treatment of patients with celiac disease who have persistent symptoms despite being on a gluten-free…
- Trial name
- NCT01396213
- Testing
- Larazotide Acetate
- Where
- 62 sites in United States, Canada
- Volunteers
- 342 people
- Sponsor
- 9 Meters Biopharma, Inc.
Celiac Disease, Coeliac Disease
A Study of Efficacy, Safety, and Tolerability of KAN-101 in People With Celiac Disease
The study goal is to evaluate the efficacy, safety, and tolerability of KAN-101 in participants with Celiac Disease (CeD)
- Trial name
- SynCeD (NCT06001177)
- Testing
- KAN-101
- Where
- 28 sites in United States, Canada and 6 more
- Volunteers
- 55 people
- Sponsor
- Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA
Eosinophilic Esophagitis, Celiac Disease
Dose Escalation Study to Evaluate an Experimental New Treatment (CALY-002) in Healthy Subjects and Subjects With Celiac Disease and Eosinophilic Esophagitis
This is a single and multiple ascending study to characterize the safety, PK, PD and clinical effect in healthy volunteers and participants with Celiac Disease and Eosinophilic Esophagitis.
- Trial name
- NCT04593251
- Testing
- CALY-002
- Where
- 13 sites in Belgium, Finland and 3 more
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- Calypso Biotech BV